PBC: HANDLE 2026
Gilead Sciences funds research to advance understanding and improve outcomes for primary biliary cholangitis (PBC), focusing on unmet needs and innovative approaches in disease management.
Funder: Gilead Sciences
Due Dates: April 20, 2026 (LOI deadline) | July 3, 2026 (Full proposal deadline)
Funding Amounts: No fixed maximum; budget must be proportional to scope. Overhead capped at 30%. Typical project duration: 18 months.
Summary: Supports research to address unmet medical needs and improve patient outcomes in primary biliary cholangitis (PBC).
Key Information: Only research from regions where Seladelpar is approved and available is eligible.
Description
This program supports research proposals focused on characterizing and addressing unmet medical needs in primary biliary cholangitis (PBC), a chronic autoimmune liver disease. The initiative seeks to advance understanding of PBC, identify gaps in current clinical approaches, and develop innovative solutions to improve patient outcomes. Proposals should generate data relevant to the PBC community and include plans for dissemination through scientific forums and journals. The program is part of Gilead’s broader commitment to inflammation research.
